Drug Efficacy

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

The decision rests on reduced C‑peptide decline seen in the PROTECT trial and global data, and the FDA requires confirmatory studies to prove real clinical benefit.